Skip to main content
. 2021 May 20;38(7):3724–3742. doi: 10.1007/s12325-021-01722-w

Fig. 6.

Fig. 6

Summary of the clinical outcome measures a annualized relapse rate (ARR) and b 24-week confirmed disability worsening over 4 years in STRIVE in the intent-to-treat (ITT) and 4-year natalizumab completer populations. Dashed lines indicate 95% confidence interval (CI)